Experimental Hematology
Volume 38, Issue 5 , Pages 351-362 , May 2010

Natural-killer cell amplification for adoptive leukemia relapse immunotherapy: Comparison of three cytokines, IL-2, IL-15, or IL-7 and impact on NKG2D, KIR2DL1, and KIR2DL2 expression

  • Véronique Decot

      Affiliations

    • Unité de Thérapie Cellulaire et Tissus, CHU Nancy, Nancy, France
    • Nancy Université, UHP-UMR CNRS 7561, Faculté de Médecine, Vandoeuvre-lès-Nancy, Nancy, France
    • Corresponding Author InformationOffprint requests to: Véronique Decot, Ph.D., Cell Therapy and Tissue Unit, CHU Nancy, allée du Morvan, 54511 Vandoeuvre les Nancy, France
    • ,
  • Laure Voillard

      Affiliations

    • Unité de Thérapie Cellulaire et Tissus, CHU Nancy, Nancy, France
    • ,
  • Véronique Latger-Cannard

      Affiliations

    • Service d'Hématologie Biologique, CHU de Nancy, Nancy, France
    • ,
  • Lamia Aissi-Rothé

      Affiliations

    • Unité de Thérapie Cellulaire et Tissus, CHU Nancy, Nancy, France
    • Nancy Université, UHP-UMR CNRS 7561, Faculté de Médecine, Vandoeuvre-lès-Nancy, Nancy, France
    • ,
  • Pascale Perrier

      Affiliations

    • Service d'Histocompatibilité, CHU Nancy, Nancy, France
    • ,
  • Jean Francois Stoltz

      Affiliations

    • Unité de Thérapie Cellulaire et Tissus, CHU Nancy, Nancy, France
    • Nancy Université, UHP-UMR CNRS 7561, Faculté de Médecine, Vandoeuvre-lès-Nancy, Nancy, France
    • ,
  • Daniele Bensoussan

      Affiliations

    • Unité de Thérapie Cellulaire et Tissus, CHU Nancy, Nancy, France
    • Nancy Université, UHP-UMR CNRS 7561, Faculté de Médecine, Vandoeuvre-lès-Nancy, Nancy, France

Received 8 July 2009 ,Revised 18 December 2009 ,Accepted 9 February 2010.

References 

  1. Barnes DW, Loutit JF. Treatment of murine leukaemia with x-rays and homologous bone marrow. II. Br J Haematol. 1957;3:241–252
  2. Fefer A. Graft-vs-tumor responses. In:  Blume KG,  Forman SJ,  Appelbaum FR editor. Thomas' Hematopoietic Cell Transplantation. 3rd ed. Oxford, UK: Blackwell publishing Ltd; 2004;p. 369–379.
  3. Bonnet D, Warren EH, Greenberg PD, Dick JE, Riddell SR. CD8(+) minor histocompatibility antigen-specific cytotoxic T lymphocyte clones eliminate human acute myeloid leukemia stem cells. Proc Natl Acad Sci U S A. 1999;96:8639–8644
  4. Hambach L, Spierings E, Goulmy E. Risk assessment in haematopoietic stem cell transplantation: minor histocompatibility antigens. Best Pract Res Clin Haematol. 2007;20:171–187
  5. Biron CA, Nguyen KB, Pien GC, Cousens LP, Salazar-Mather TP. Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu Rev Immunol. 1999;17:189–220
  6. Trinchieri G. Biology of natural killer cells. Adv Immunol. 1989;47:187–376
  7. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295:2097–2100
  8. Velardi A. Role of KIRs and KIR ligands in hematopoietic transplantation. Curr Opin Immunol. 2008;20:581–587
  9. Hsu KC, Keever-Taylor CA, Wilton A, et al. Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood. 2005;105:4878–4884
  10. Verheyden S, Schots R, Duquet W, Demanet C. A defined donor activating natural killer cell receptor genotype protects against leukemic relapse after related HLA-identical hematopoietic stem cell transplantation. Leukemia. 2005;19:1446–1451
  11. Lang P, Pfeiffer M, Handgretinger R, et al. Clinical scale isolation of T cell-depleted CD56+ donor lymphocytes in children. Bone Marrow Transplant. 2002;29:497–502
  12. Bamford RN, Grant AJ, Burton JD, et al. The interleukin (IL) 2 receptor beta chain is shared by IL-2 and a cytokine, provisionally designated IL-T, that stimulates T-cell proliferation and the induction of lymphokine-activated killer cells. Proc Natl Acad Sci U S A. 1994;91:4940–4944
  13. Giri JG, Ahdieh M, Eisenman J, et al. Utilization of the beta and gamma chains of the IL-2 receptor by the novel cytokine IL-15. EMBO J. 1994;13:2822–2830
  14. Rosenberg SA, Lotze MT, Muul LM, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med. 1985;313:1485–1492
  15. McKenna DH, Sumstad D, Bostrom N, et al. Good manufacturing practices production of natural killer cells for immunotherapy: a six-year single-institution experience. Transfusion. 2007;47:520–528
  16. Farag SS, Fehniger TA, Ruggeri L, Velardi A, Caligiuri MA. Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect. Blood. 2002;100:1935–1947
  17. Curtis RE, Travis LB, Rowlings PA, et al. Risk of lymphoproliferative disorders after bone marrow transplantation: A multi-institutional study. Blood. 1999;94:2208–2216
  18. Passweg JR, Stern M, Koehl U, Uharek L, Tichelli A. Use of natural killer cells in hematopoetic stem cell transplantation. Bone Marrow Transplant. 2005;35:637–643
  19. Bethge WA, Faul C, Bornhauser M, et al. Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: An update. Blood Cells Mol Dis. 2008;40:13–19
  20. Berg M, Lundqvist A, McCoy P, et al. Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells. Cytotherapy. 2009;11:341–355
  21. Koehl U, Esser R, Zimmermann S, et al. Ex vivo expansion of highly purified NK cells for immunotherapy after haploidentical stem cell transplantation in children. Klin Padiatr. 2005;217:345–350
  22. Alici E, Sutlu T, Bjorkstrand B, et al. Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components. Blood. 2008;111:3155–3162
  23. Carson WE, Fehniger TA, Haldar S, et al. A potential role for interleukin-15 in the regulation of human natural killer cell survival. J Clin Invest. 1997;99:937–943
  24. Cooper MA, Bush JE, Fehniger TA, et al. In vivo evidence for a dependence on interleukin 15 for survival of natural killer cells. Blood. 2002;100:3633–36338
  25. Szczepanski MJ, Szajnik M, Welsh A, Foon KA, Whiteside TL, Boyiadzis M. Interleukin-15 enhances natural killer cell cytotoxicity in patients with acute myeloid leukemia by upregulating the activating NK cell receptors. Cancer Immunol Immunother. 2010;59:73–79
  26. Lum JJ, Schnepple DJ, Nie Z, et al. Differential effects of interleukin-7 and interleukin-15 on NK cell anti-human immunodeficiency virus activity. J Virol. 2004;78:6033–6042
  27. Poggi A, Catellani S, Garuti A, Pierri I, Gobbi M, Zocchi MR. Effective in vivo induction of NKG2D ligands in acute myeloid leukaemias by all-trans-retinoic acid or sodium valproate. Leukemia. 2009;23:641–648
  28. Cerwenka A, Lanier LL. NKG2D ligands: unconventional MHC class I-like molecules exploited by viruses and cancer. Tissue Antigens. 2003;61:335–343

PII: S0301-472X(10)00051-2

doi: 10.1016/j.exphem.2010.02.006

Experimental Hematology
Volume 38, Issue 5 , Pages 351-362 , May 2010

Article Tools

* Image Usage & Resolution